Perspective Therapeutics (NYSE:CATX) Price Target Lowered to $15.00 at Royal Bank of Canada

Perspective Therapeutics (NYSE:CATX) had its target price reduced by research analysts at Royal Bank of Canada from $16.00 to $15.00 in a research note issued on Thursday,Benzinga reports. The firm currently has an “outperform” rating on the stock.

A number of other brokerages have also recently issued reports on CATX. Scotiabank assumed coverage on Perspective Therapeutics in a report on Friday, March 7th. They set a “sector outperform” rating and a $15.00 price objective for the company. Brookline Capital Management raised Perspective Therapeutics to a “strong-buy” rating in a report on Monday, March 10th. Lifesci Capital upgraded Perspective Therapeutics to a “strong-buy” rating in a research report on Thursday, March 6th. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Perspective Therapeutics in a research report on Wednesday, March 19th. Finally, Wedbush reaffirmed an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a research report on Wednesday. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $14.44.

Perspective Therapeutics Stock Down 4.3 %

CATX stock opened at $2.20 on Thursday. The company has a fifty day moving average price of $2.94 and a two-hundred day moving average price of $6.42. Perspective Therapeutics has a one year low of $2.19 and a one year high of $19.05.

Hedge Funds Weigh In On Perspective Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Charles Schwab Investment Management Inc. boosted its stake in Perspective Therapeutics by 221.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 433,522 shares of the company’s stock valued at $5,788,000 after buying an additional 298,778 shares in the last quarter. State Street Corp lifted its holdings in shares of Perspective Therapeutics by 119.6% in the third quarter. State Street Corp now owns 2,190,239 shares of the company’s stock worth $29,240,000 after acquiring an additional 1,192,812 shares during the last quarter. Janus Henderson Group PLC boosted its stake in shares of Perspective Therapeutics by 8.0% in the 3rd quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock valued at $64,014,000 after purchasing an additional 355,685 shares in the last quarter. FMR LLC grew its holdings in shares of Perspective Therapeutics by 3,994.9% during the 3rd quarter. FMR LLC now owns 5,504,822 shares of the company’s stock valued at $73,489,000 after purchasing an additional 5,370,392 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its stake in shares of Perspective Therapeutics by 1,302.7% during the third quarter. BNP Paribas Financial Markets now owns 47,565 shares of the company’s stock worth $635,000 after buying an additional 44,174 shares during the last quarter. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.